Digest Network Come funziona
Network
/
Società
Ac
Non verificato

Actio Biosciences

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

17 comunicati stampa

Guarda tutti i comunicati
05/12/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Industria
Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
24/11/2025
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Eventi
Industria
Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
23/09/2025
Industria
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
10/09/2025
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Eventi
Actio Biosciences to Participate in TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
30/07/2025
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
Actio Biosciences Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
07/07/2025
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Eventi
Fiere
Actio Biosciences to Participate in Evercore Emerging Private Biotech Conference
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
18/06/2025
Biotecnologia
Igiene alimentare
Salute
Finanza
Sanità
Farmaceutica
Associazioni/Professionisti
Management
Attrezzature medico-sanitarie
Medicina - Varie
Industria
Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
09/04/2025
Fiere
Scienza
Biotecnologia
Medicina - Varie
Sanità
Salute
Farmaceutica
Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
03/03/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-0871, a Novel TRPV4 Inhibitor, for the Treatment of Charcot Marie Tooth Disease 2C
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0
25/02/2025
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Industria
Actio Biosciences to Participate in Upcoming Investor Conferences
Fonte
Actio Biosciences
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0